Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2022 Jan 13;651:734-746. doi: 10.1021/acs.jmedchem.1c01810.
Show Gene links
Show Anatomy links
Derivatives of (R)-3-(5-Furanyl)carboxamido-2-aminopropanoic Acid as Potent NMDA Receptor Glycine Site Agonists with GluN2 Subunit-Specific Activity.
Zhao F
,
Atxabal U
,
Mariottini S
,
Yi F
,
Lotti JS
,
Rouzbeh N
,
Liu N
,
Bunch L
,
Hansen KB
,
Clausen RP
.
???displayArticle.abstract???
NMDA receptors mediate glutamatergic neurotransmission and are therapeutic targets due to their involvement in a variety of psychiatric and neurological disorders. Here, we describe the design and synthesis of a series of (R)-3-(5-furanyl)carboxamido-2-aminopropanoic acid analogues 8a-s as agonists at the glycine (Gly) binding site in the GluN1 subunit, but not GluN3 subunits, of NMDA receptors. These novel analogues display highly variable potencies and agonist efficacies among the NMDA receptor subtypes (GluN1/2A-D) in a manner dependent on the GluN2 subunit. Notably, compound 8p is identified as a potent partial agonist at GluN1/2C (EC50 = 0.074 μM) with an agonist efficacy of 28% relative to activation by Gly and virtually no agonist activity at GluN1/2A, GluN1/2B, and GluN1/2D. Thus, these novel agonists can modulate the activity of specific NMDA receptor subtypes by replacing the full endogenous agonists Gly or d-serine (d-Ser), thereby providing new opportunities in the development of novel therapeutic agents.
???displayArticle.pubmedLink???
34918931
???displayArticle.pmcLink???PMC9437973 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Awobuluyi,
Subunit-specific roles of glycine-binding domains in activation of NR1/NR3 N-methyl-D-aspartate receptors.
2007, Pubmed
Awobuluyi,
Subunit-specific roles of glycine-binding domains in activation of NR1/NR3 N-methyl-D-aspartate receptors.
2007,
Pubmed
Bae,
SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function.
2021,
Pubmed
Balu,
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
2015,
Pubmed
Bergeron,
Modulation of N-methyl-D-aspartate receptor function by glycine transport.
1998,
Pubmed
Billups,
Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse.
2003,
Pubmed
Chatterton,
Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits.
2002,
Pubmed
,
Xenbase
Chen,
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.
2008,
Pubmed
,
Xenbase
Cheng,
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
1973,
Pubmed
Christopoulos,
Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log.
1998,
Pubmed
Conn,
Pharmacology and functions of metabotropic glutamate receptors.
1997,
Pubmed
Coyle,
NMDA receptor and schizophrenia: a brief history.
2012,
Pubmed
Davis,
Effects of D-cycloserine on extinction: translation from preclinical to clinical work.
2006,
Pubmed
Dravid,
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.
2010,
Pubmed
,
Xenbase
Farlow,
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
2004,
Pubmed
Goff,
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
2015,
Pubmed
Hanada,
Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors.
2020,
Pubmed
Hansen,
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.
2021,
Pubmed
Hansen,
Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.
2014,
Pubmed
,
Xenbase
Hansen,
Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Hofmann,
D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.
2015,
Pubmed
Hood,
D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics.
1989,
Pubmed
Ishiwata,
Neuronal serine racemase regulates extracellular D-serine levels in the adult mouse hippocampus.
2015,
Pubmed
Jessen,
Identification of AICP as a GluN2C-Selective N-Methyl-d-Aspartate Receptor Superagonist at the GluN1 Glycine Site.
2017,
Pubmed
,
Xenbase
Kvist,
Structure-based discovery of antagonists for GluN3-containing N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Lemoine,
Ligand-gated ion channels: new insights into neurological disorders and ligand recognition.
2012,
Pubmed
Liu,
Modulation of burst firing of neurons in nucleus reticularis of the thalamus by GluN2C-containing NMDA receptors.
2019,
Pubmed
Liu,
Facilitation of GluN2C-containing NMDA receptors in the external globus pallidus increases firing of fast spiking neurons and improves motor function in a hemiparkinsonian mouse model.
2021,
Pubmed
Madry,
Principal role of NR3 subunits in NR1/NR3 excitatory glycine receptor function.
2007,
Pubmed
,
Xenbase
Maolanon,
Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites.
2017,
Pubmed
,
Xenbase
Mishizen-Eberz,
Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology.
2004,
Pubmed
Mohn,
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.
1999,
Pubmed
Niswender,
Metabotropic glutamate receptors: physiology, pharmacology, and disease.
2010,
Pubmed
Olivares,
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
2012,
Pubmed
Pin,
The metabotropic glutamate receptors: structure and functions.
1995,
Pubmed
Schade,
D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
2016,
Pubmed
Sheinin,
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine.
2001,
Pubmed
,
Xenbase
Singewald,
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.
2015,
Pubmed
Snyder,
NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.
2020,
Pubmed
Szakacs,
The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
2012,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Urwyler,
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
2009,
Pubmed
Williams,
Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
1993,
Pubmed
,
Xenbase
Yao,
Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A.
2006,
Pubmed
Yao,
Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors.
2008,
Pubmed
Yi,
Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors.
2016,
Pubmed
,
Xenbase
